Treatment of idiopathic anaphylaxis with omalizumab

Ann Allergy Asthma Immunol. 2019 Dec;123(6):612-613. doi: 10.1016/j.anai.2019.09.020. Epub 2019 Sep 27.

Authors

Maria C Sanchez-Valenzuela¹, Juan C Garcia-Saucedo¹, Gabriel Motoa¹, Ismael Carrillo-Martin¹, Alexei Gonzalez-Estrada²

Affiliations

¹ Division of Pulmonary, Allergy, and Sleep Medicine, Department of Medicine, Mayo Clinic, Jacksonville, Florida.
² Division of Pulmonary, Allergy, and Sleep Medicine, Department of Medicine, Mayo Clinic, Jacksonville, Florida. Electronic address: gonzalez.alexei@mayo.edu.

PMID: 31568858
DOI: 10.1016/j.anai.2019.09.020

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Anaphylaxis / drug therapy*
Anti-Allergic Agents / therapeutic use*
Anti-Asthmatic Agents / therapeutic use*
Female
Humans
Omalizumab / therapeutic use*
Treatment Outcome

Substances

Anti-Allergic Agents
Anti-Asthmatic Agents
Omalizumab